PRESS RELEASE: Arena Pharmaceuticals Raises $109 Million

Arena Pharmaceuticals Raises $109 Million

SAN DIEGO, Nov. 1 -- Arena Pharmaceuticals announced today the pricing of its public offering of 11,000,000 shares of its common stock at a public offering price of $9.91 per share. All of the shares are being offered by Arena. The underwriters have a 30-day option to purchase up to an additional 1,650,000 shares of common stock to cover over-allotments, if any.

CIBC World Markets and UBS Investment Bank are acting as joint book-running managers in this offering.

A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. Sales of shares pursuant to this offering may be made only by means of the final prospectus supplement and related prospectus, copies of which can be obtained from CIBC World Markets by email at [email protected], by phone at 212.667.7200, by fax at 212.667.6303, or by mail at CIBC World Markets, Attn: USE Prospectus Department, 425 Lexington Avenue, 5th floor, New York, NY 10017, or from UBS Investment Bank, Prospectus Department, 299 Park Avenue, 8th floor, New York, NY 10171 or by phone at 888.827.7275. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.